The Biotechnology Industry Organization has examined the 1,400-page health care reform bill sponsored by Senate Majority Leader George Mitchell, D-Maine, and identified the provisions it believes would "adversely affect research" by the biotechnology industry. Following is the list, along with the BIO's arguments about the issues.

Rebates on prescription drugs covered under Medicare Part B

Summary BIO arguments
Would move drugs now covered under Part B(administered "incident" to a physician's service) into the new Medicare prescription drug benefit, which would require rebates Biotech drugs disproportionately affected because they are administered in large part through transfusion or injection "incident" to a physician's service.
  Creates additional tax for biotech drugs already on market.
  Creates incentives, particularly for chemotherapies, to admit patients into hospitals.